Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IgA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    681 result(s) found for: IgA. Displaying page 9 of 35.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2014-003725-17 Sponsor Protocol Number: D2213C00001 Start Date*: 2015-04-15
    Sponsor Name:MedImmune
    Full Title: A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004099-20 Sponsor Protocol Number: LP0160-1510 Start Date*: 2020-11-25
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy and safety comparison of brodalumab versus guselkumab in adult subjects with moderate-to-severe plaque psoriasis and inadequate response to ustekinumab.
    Medical condition: adult subjects with moderate-to-severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) AT (Prematurely Ended) FR (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) DK (Completed) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001744-38 Sponsor Protocol Number: RD.06.SPR.18132 Start Date*: 2015-03-25
    Sponsor Name:GALDERMA R&D, LLC
    Full Title: A multicenter, randomized, double blind, parallel group, vehicle controlled, study of the safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 8 weeks in pediatric subjects (2...
    Medical condition: Psoriasis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005170-38 Sponsor Protocol Number: CAIN457A2323 Start Date*: 2016-09-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumAb injections with 2 mL pre-fiLLed syringes...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LV (Completed) BE (Completed) ES (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2019-001887-31 Sponsor Protocol Number: RD.06.SPR.118161 Start Date*: 2020-02-19
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) GB (GB - no longer in EU/EEA) DE (Completed) LT (Completed) NL (Completed) AT (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003774-41 Sponsor Protocol Number: EFC16459 Start Date*: 2021-03-17
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlle...
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10029263 Neurodermatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000839-17 Sponsor Protocol Number: CASM981C2439 Start Date*: 2005-04-11
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 16-week, randomized, multi-center, parallel-group, pimecrolimus-blinded, controlled study (4-week treatment period followed by 12-week observational period) to evaluate the safety of concomitant ...
    Medical condition: Treatment of severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012438 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000492-32 Sponsor Protocol Number: AMIII Start Date*: 2019-01-14
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections
    Medical condition: mechanically ventilated patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000747-11 Sponsor Protocol Number: GP17-301 Start Date*: 2013-11-25
    Sponsor Name:Hexal AG
    Full Title: A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira® in patients with moderate t...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001632-21 Sponsor Protocol Number: M518101-EU04 Start Date*: 2013-10-01
    Sponsor Name:Maruho Europe Limited
    Full Title: A randomized, double-blind, parallel group phase III multi-center trial to compare twice daily topical application of M518101, Daivonex® and vehicle in patients with plaque psoriasis
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) PL (Completed) BG (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003307-19 Sponsor Protocol Number: NAC-GED-0507-ACN-01-18 Start Date*: 2019-09-18
    Sponsor Name:PPM SERVICES S.A.
    Full Title: A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 2 and 5%, applied once daily for 12 weeks in patient...
    Medical condition: facial acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000783-29 Sponsor Protocol Number: GBR830-204 Start Date*: 2018-12-18
    Sponsor Name:Ichnos Sciences SA
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis.
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002573-21 Sponsor Protocol Number: B7451029 Start Date*: 2019-02-11
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEB...
    Medical condition: Moderate to severe atopic dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) CZ (Completed) LV (Completed) FR (Completed) HU (Completed) AT (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000533-39 Sponsor Protocol Number: CAIN457A2302E1 Start Date*: 2012-06-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subj...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed) LV (Completed) SE (Completed) LT (Completed) ES (Completed) BE (Completed) EE (Completed) GB (Completed) DE (Completed) FI (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004427-24 Sponsor Protocol Number: CCP-020-301 Start Date*: 2017-08-24
    Sponsor Name:Castle Creek Pharmaceuticals, LLC
    Full Title: An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis ...
    Medical condition: Epidermolysis Bullosa Simplex (EBS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003712-45 Sponsor Protocol Number: INCB18424-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic ...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003713-18 Sponsor Protocol Number: INCB18424-304 Start Date*: Information not available in EudraCT
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic ...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) BG (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-005025-37 Sponsor Protocol Number: RD.03.SPR.114322 Start Date*: 2017-08-30
    Sponsor Name:GALDERMA R&D, SNC
    Full Title: A randomized, double-blind, multi-center, parallel-group, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis su...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10014184 Eczema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002771-33 Sponsor Protocol Number: ATX201-207 Start Date*: 2019-09-25
    Sponsor Name:UNION therapeutics A/S
    Full Title: A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults with Mild to Moderate Atopic De...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-002607-19 Sponsor Protocol Number: 77474462HDS2001 Start Date*: 2021-10-07
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a/2b, Multicenter, Randomized, Placebo and Active Comparator-controlled, Double-Blind, Dose-ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment...
    Medical condition: Moderate to Severe Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended) ES (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 12:21:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA